Theranexus Société Anonyme (ALTHX.PA)
EUR 0.64
(32.37%)
EUR 0.64
(32.37%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.64 Million EUR | -25.48% |
| 2022 | 4.88 Million EUR | -8.22% |
| 2021 | 5.32 Million EUR | -6.63% |
| 2020 | 5.7 Million EUR | 105.38% |
| 2019 | 2.77 Million EUR | -19.83% |
| 2018 | 3.46 Million EUR | 640.13% |
| 2017 | 468.16 Thousand EUR | -73.32% |
| 2016 | 1.75 Million EUR | 250.64% |
| 2015 | 500.46 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.93 Million EUR | 0.0% |
| 2023 Q2 | 3.9 Million EUR | 0.0% |
| 2023 Q4 | 3.64 Million EUR | 0.0% |
| 2023 FY | 3.64 Million EUR | -25.48% |
| 2022 Q2 | 5.58 Million EUR | 0.0% |
| 2022 FY | 4.88 Million EUR | -8.22% |
| 2022 Q4 | 4.88 Million EUR | 0.0% |
| 2021 Q2 | 5.57 Million EUR | 0.0% |
| 2021 FY | 5.32 Million EUR | -6.63% |
| 2021 Q4 | 5.32 Million EUR | 0.0% |
| 2020 Q2 | 4.18 Million EUR | 0.0% |
| 2020 Q4 | 5.7 Million EUR | 0.0% |
| 2020 FY | 5.7 Million EUR | 105.38% |
| 2019 FY | 2.77 Million EUR | -19.83% |
| 2019 Q4 | 2.77 Million EUR | 0.0% |
| 2019 Q2 | 3.15 Million EUR | 0.0% |
| 2018 Q2 | 355.14 Thousand EUR | 0.0% |
| 2018 Q4 | 3.46 Million EUR | 0.0% |
| 2018 FY | 3.46 Million EUR | 640.13% |
| 2017 Q2 | 1.79 Million EUR | 0.0% |
| 2017 FY | 468.16 Thousand EUR | -73.32% |
| 2017 Q4 | 468.16 Thousand EUR | 0.0% |
| 2016 Q4 | 1.75 Million EUR | 0.0% |
| 2016 FY | 1.75 Million EUR | 250.64% |
| 2015 FY | 500.46 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -7.464% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 93.432% |
| Adocia SA | 13.08 Million EUR | 72.165% |
| Aelis Farma SA | 4.03 Million EUR | 9.782% |
| Biophytis S.A. | 8.27 Million EUR | 55.949% |
| Advicenne S.A. | 17.42 Million EUR | 79.093% |
| genOway Société anonyme | 7.23 Million EUR | 49.636% |
| IntegraGen SA | 1.12 Million EUR | -223.9% |
| Medesis Pharma S.A. | 1.2 Million EUR | -203.585% |
| Neovacs S.A. | 650 Thousand EUR | -460.465% |
| NFL Biosciences SA | 62.17 Thousand EUR | -5759.396% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 16.378% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -34.09% |
| Sensorion SA | 2.86 Million EUR | -26.988% |
| TME Pharma N.V. | 1.16 Million EUR | -212.437% |
| Valbiotis SA | 6.87 Million EUR | 47.034% |
| TheraVet SA | 1.15 Million EUR | -214.09% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 59.513% |
| argenx SE | 18.1 Million EUR | 79.879% |
| BioSenic S.A. | 28.16 Million EUR | 87.064% |
| Celyad Oncology SA | 902 Thousand EUR | -303.883% |
| DBV Technologies S.A. | 13.01 Million USD | 72.017% |
| Galapagos NV | 9.59 Million EUR | 62.036% |
| Genfit S.A. | 70.17 Million EUR | 94.809% |
| GeNeuro SA | 7.73 Million EUR | 52.919% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | 31.186% |
| Innate Pharma S.A. | 39.89 Million EUR | 90.868% |
| Inventiva S.A. | 37.4 Million EUR | 90.261% |
| MaaT Pharma SA | 14.07 Million EUR | 74.117% |
| MedinCell S.A. | 58.96 Million EUR | 93.821% |
| Nanobiotix S.A. | 50.56 Million EUR | 92.795% |
| Onward Medical N.V. | 16.87 Million EUR | 78.41% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 73.384% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 92.046% |
| Oxurion NV | 12.33 Million EUR | 70.464% |
| Pharming Group N.V. | 155.29 Million EUR | 97.654% |
| Poxel S.A. | 46.9 Million EUR | 92.232% |
| GenSight Biologics S.A. | 18.42 Million EUR | 80.231% |
| Transgene SA | 1.25 Million EUR | -189.819% |
| Financière de Tubize SA | 79.2 Million EUR | 95.4% |
| UCB SA | 3.03 Billion EUR | 99.88% |
| Valneva SE | 208.81 Million EUR | 98.255% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -9486.897% |